Guerbet

Guerbet: Guerbet announces a change in governance for its Artificial Intelligence projects

03 Nov 2022 12:04:18 By Nasdaq GlobeNewswire

Guerbet: Revenue at September 30, 2022

20 Oct 2022 10:45:00 By Nasdaq GlobeNewswire

Guerbet obtains one million euros of public funding from Bpifrance (France 2030 investment plan) for a project developing artificial intelligence for the early detection of pancreatic cancer

26 Sep 2022 11:00:00 By Nasdaq GlobeNewswire

Guerbet announces U.S. Food and Drug Administration (FDA) approval of Elucirem™ (Gadopiclenol)

21 Sep 2022 12:00:00 By Nasdaq GlobeNewswire

Guerbet: 2022 half-year results

21 Sep 2022 10:45:00 By Nasdaq GlobeNewswire

Guerbet: Revenue at June 30, 2022

21 Jul 2022 10:45:00 By Nasdaq GlobeNewswire

Guerbet receives EMA acceptance of EluciremTM as the Brand Name for Gadopiclenol

13 Jun 2022 01:30:00 By Nasdaq GlobeNewswire

Guerbet: Q1 2022 revenue

21 Apr 2022 10:45:00 By Nasdaq GlobeNewswire

Guerbet strengthens its Executive Committee with the appointment of Charlotte Bamière, General Counsel

06 Apr 2022 01:30:00 By Nasdaq GlobeNewswire

Guerbet - Gadopiclenol Marketing Authorization dossier submissions accepted for review by EMA and FDA - Priority Review granted by US-FDA March 28, 2022

29 Mar 2022 11:05:55 By Nasdaq GlobeNewswire

Guerbet: 2021 annual results

23 Mar 2022 11:45:00 By Nasdaq GlobeNewswire

Guerbet: Guerbet expands portfolio with microcatheters and guidewires for interventional imaging and embolization

07 Mar 2022 11:00:48 By Nasdaq GlobeNewswire

Guerbet: 2021 revenue

10 Feb 2022 10:54:31 By Nasdaq GlobeNewswire

Guerbet: 2021 Corporate Social Responsibility Gaïa-Index: Guerbet consolidates its position as leader in the “Healthcare” category

04 Jan 2022 11:02:01 By Nasdaq GlobeNewswire

Guerbet and Bracco Imaging Announce a Global Strategic Collaboration Agreement for Gadopiclenol

14 Dec 2021 00:00:00 By Nasdaq GlobeNewswire

Guerbet: Revenue at September 30, 2021

21 Oct 2021 10:46:04 By Nasdaq GlobeNewswire

Guerbet: Guerbet contributes to the NH TherAguix IPO on Euronext Growth, a specialist in innovative biotechnologies for precision radiotherapy

29 Sep 2021 11:00:54 By Nasdaq GlobeNewswire

Guerbet: 2021 half-year results

22 Sep 2021 10:54:05 By Nasdaq GlobeNewswire

Guerbet: Revenue at June 30, 2021

22 Jul 2021 10:46:33 By Nasdaq GlobeNewswire

Marc Massiot appointed to Guerbet’s Board of Directors

31 May 2021 11:00:00 By Nasdaq GlobeNewswire